223127-83-1

Basic information

• Product Name: ethyl 2-(4-chlorophenoxy)-3-(4-hydroxyphenyl)propionate
• Synonyms: ethyl 2-(4-chlorophenoxy)-3-(4-hydroxyphenyl)propionate
• CAS NO: 223127-83-1
• Molecular Weight: 320.773
• Mol File: 223127-83-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ethyl 2-(4-chlorophenoxy)-3-(4-hydroxyphenyl)propionate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-chlorophenoxy)-3-(4-hydroxyphenyl)propionate(223127-83-1)
• EPA Substance Registry System: ethyl 2-(4-chlorophenoxy)-3-(4-hydroxyphenyl)propionate(223127-83-1)

Safety Data

• Hazardous Substances Data: 223127-83-1(Hazardous Substances Data)

Upstream product

• 62517-34-4 ethyl 2-hydroxy-3-(4-hydroxyphenyl)propionate 
• 223127-82-0 ethyl 3-(4-benzyloxyphenyl)-2-(4-chlorophenoxy)propionate 
• 64-19-7 acetic acid 
• 141109-83-3 ethyl 3-(4-benzyloxyphenyl)lactate 

Downstream Products

• 223127-81-9 ethyl 3-[4-(2-tert-butoxycarbonylaminoethoxy)phenyl]-2-(4-chlorophenoxy)propionate 
• 223125-76-6 ethyl 2-(4-chlorophenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate 

Relevant articles and documents

Synthesis and biological activity of novel α-substituted β-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents

We previously reported the identification of novel oximes having 5-benzyl-2,4-thiazolidinedione with antihyperglycemic activity. We now report the synthesis and biological activity of a novel series of oximes and amides having α-substituted-β-phenylpropionic acids. In this series, we obtained potent PPARα/γ dual agonist (S)-9d, with which activation of PPARα and PPARγ was considerably more potent than that of the reference compounds GW9578 22 and rosiglitazone 3, respectively. This means (S)-9d is of the strongest class of PPARα/γ dual agonists. In the course of this study, we also obtained 8h, which indicated potent plasma glucose lowering effect in spite of weak PPARα/γ agonistic activity.

Amidocarboxylic acid derivatives

Amidocarboxylic acid derivatives of the formula: wherein R1 represents a hydrogen atom, etc.; R2 represents an alkylene group; R3 represents a hydrogen atom, etc.; R4 represents a hydrogen atom, etc.; X represents a substituted or unsubstituted aryl group, etc.,; Y represents an oxygen atom, etc.; Z represents an alkylene group, etc.; and W represents an alkyl group, etc.; and pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof are useful as the active ingredient of pharmaceutical compositions. They may be used to treat specified diseases, including diabetes mellitus, hyperlipemia, arteriosclerosis, hypertension, etc.